Inclusive photoproduction of vector quarkonium in ultra-peripheral collisions at the LHC.

We explore the possibility of using ultra-periphe- ral proton-lead collisions at the LHC to study inclusive vector-quarkonium photoproduction, that occurs when a quasi-real photon emitted by a fully stripped lead ion breaks a proton to produce a vector quarkonium. Owing to the extremely large energies of the colliding hadrons circulating in the LHC, the range of accessible photon-nucleon centre-of-mass energies, , largely exceeds what has been and will be studied at lepton-hadron colliders, HERA and the EIC. We perform a tune to HERA photoproduction data, use this tune to predict the yields of photoproduced , and estimate the corresponding transverse-momentum reach at LHC experiments.

Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.

Background: Tafenoquine (TQ) is an 8-aminoquinoline (8AQ) that has been tested in several Phase II and Phase III clinical studies and is currently in late stage development as an anti-malarial prophylactic agent. NPC-1161B is a promising 8AQ in late preclinical development. It has recently been reported that the 8AQ drug primaquine requires metabolic activation by CYP 2D6 for efficacy in humans and in mice, highlighting the importance of pharmacogenomics in the target population when administering primaquine.